The first study, published yesterday in Clinical Infectious Diseases, includes results of a phase 3 clinical trial (MELODY), ...

New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...

Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...

The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...

University of Michigan and Centers for Disease Control and Prevention (CDC) investigators determined that both maternal ...

A recently approved immunization drug is helping to limit the severity of a respiratory disease that afflicts young children ...

RSV cases, hospitalisations and ICU admissions notified in 12 weeks to mid-November were between six and seven times lower ...

Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness.

RSV season is beginning, but for the first time, parents can access an effective treatment to protect their infants from this common but dangerous virus.

Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...

RSV is the most common cause of hospitalization in infants under 1 year old. The infection can spread to the lungs and cause ...

Now that colder temperatures have arrived, the Illinois Department of Public Health (IDPH) is reminding Illinoisans to ...